HIT Policy Committee Advisory Meeting; Notice of Two-Day Meeting, 50211-50212 [E9-23460]
Download as PDF
Federal Register / Vol. 74, No. 188 / Wednesday, September 30, 2009 / Notices
Federal Maritime Commission an
application for license as a Non-VesselOperating Common Carrier and Ocean
Freight Forwarder—Ocean
Transportation Intermediary pursuant to
section 19 of the Shipping Act of 1984
as amended (46 U.S.C. Chapter 409 and
46 CFR part 515).
Persons knowing of any reason why
the following applicants should not
receive a license are requested to
contact the Office of Transportation
Intermediaries, Federal Maritime
Commission, Washington, DC 20573.
Non-Vessel-Operating Common Carrier
Ocean Transportation Intermediary
Applicants
Ocean Freight Forwarder—Ocean
Transportation Intermediary
Applicants
EP Logistics, LLC, 7 Founders Blvd.,
Ste. E, El Paso, TX 79906, Officer:
Octavio Saavedra, Member
(Qualifying Individual).
Concord Express Cargo, Inc., 172–14
119th Avenue, Jamaica Queens, NY
11434, Officers: Christopher E.
Okafor, President (Qualifying
Individual), Margaret X. Burnes,
Secretary.
September 25, 2009.
Tanga S. FitzGibbon,
Assistant Secretary.
[FR Doc. E9–23568 Filed 9–29–09; 8:45 am]
BILLING CODE 6730–01–P
Non-Vessel-Operating Common Carrier
and Ocean Freight Forwarder
Transportation Intermediary
Applicants
CPrice-Sewell on DSKGBLS3C1PROD with NOTICES
Avango Logistics LLC, 552 N York Road,
Bensenville, IL 60106, Officers:
Konstantin B. Selikhov, Member
(Qualifying Individual), Rostislav
Chagovets, Member.
Office of the National Coordinator for
Health Information Technology
HYH International Cargo Services, Inc.,
dba H.Y.H. Container Line, 9107 NW
105th Way, Medley, FL 33178,
Officer: Hans G. Hofmann, President
(Qualifying Individual).
Ocean Star International, Inc., 10880
Wiles Road, Coral Springs, FL 33078,
Officer: Joshua S. Morales, President
(Qualifying Individual).
Container Loading Solutions
International USA, LLC, 755 North
Busse Highway, Ste. 217, Bensenville,
IL 60106, Officer: Paul J. Gibbs,
President (Qualifying Individual).
Fleur De Lis Worldwide LLC, 8302
Shady Ace Lane, Humble, TX 77346,
Officer: Julie A. Turpin, President
(Qualifying Individual).
Consolcargo USA Inc. dba CSC
Consolidators, 10925 NW 27th Street,
Ste. 102, Miami, FL 33172, Officers:
Rocio D. Lugo, Director (Qualifying
Individual), Peter Thomas, Vice
President.
A Cargo Inc., 4634 E. Marginal Way S.,
Ste. C–120, Seattle, WA 98134–2328,
Officers: Marcio Fanti, President,
Patrick P. Policarpio, Vice President
(Qualifying Individuals).
DNIPRO LLC, 645 West 1st Avenue,
Roselle, NJ 07203, Officers: Yelena
Cherepashenskaya, Manager
(Qualifying Individual), Igor Pluta,
President.
Target Logistic Services, Inc., 1400
Glenn Curtiss Street, Carson, CA
90746, Officer: Thomas F. Donahue,
III, Vice President (Qualifying
Individual).
VerDate Nov<24>2008
14:56 Sep 29, 2009
Jkt 217001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
HIT Policy Committee Advisory
Meeting; Notice of Two-Day Meeting
AGENCY: Office of the National
Coordinator for Health Information
Technology, HHS.
ACTION: Notice of meeting.
This notice announces a forthcoming
meeting of a public advisory committee
of the Office of the National Coordinator
for Health Information Technology
(ONC). The meeting will be open to the
public.
Name of Committee: HIT Policy
Committee.
General Function of the Committee:
To provide recommendations to the
National Coordinator on a policy
framework for the development and
adoption of a nationwide health
information technology infrastructure
that permits the electronic exchange and
use of health information as is
consistent with the Federal Health IT
Strategic Plan and that includes
recommendations on the areas in which
standards, implementation
specifications, and certification criteria
are needed.
Date and Time: The two-day meeting
will be held on October 27 and October
28, 2009, from 10 a.m. to 5:15 p.m./
Eastern Time on October 27th, and 8:30
a.m. to 3 p.m./Eastern Time on October
28th.
Location: The Omni Shoreham Hotel,
2500 Calvert Street, NW., Washington,
DC. The hotel telephone number is 202–
234–0700.
Contact Person: Judy Sparrow, Office
of the National Coordinator, HHS, 330 C
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
50211
Street, SW., Washington, DC 20201,
202–205–4528, Fax: 202–690–6079, email: judy.sparrow@hhs.gov. Please call
the contact person for up-to-date
information on this meeting. A notice in
the Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Agenda: The committee will hear
presentations from the Meaningful Use,
Certification/Adoption, and Information
Exchange Workgroups. In addition,
invited experts will provide testimony
on the mapping of core Meaningful Use
objectives and existing measures to
medical specialties, small practices, and
small hospitals. ONC intends to make
background material available to the
public no later than two (2) business
days prior to the meeting. If ONC is
unable to post the background material
on its Web site prior to the meeting, it
will be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posed on ONC’s Web site after
the meeting, at https://healthit.hhs.gov.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before October 18, 2009.
Oral comments from the pubic will be
scheduled approximately 5 p.m./Eastern
Time on October 27th, and 12:30 p.m./
Eastern Time on October 28th. Time
allotted for each public comment is
limited to two minutes. If the number of
speakers requesting to comment is
greater than can be reasonably
accommodated during the scheduled
open public hearing session, ONC will
take written comments after the meeting
until close of business.
Persons attending ONC’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
ONC welcomes the attendance of the
public at its advisory committee
meetings. Seating is limited at the
location, and ONC will make every
effort to accommodate persons with
physical disabilities or special needs. If
you require special accommodations
due to a disability, please contact Judy
Sparrow at least seven (7) days in
advance of the meeting.
ONC is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://healthit.hhs.gov for procedures
on public conduct during advisory
committee meetings.
E:\FR\FM\30SEN1.SGM
30SEN1
50212
Federal Register / Vol. 74, No. 188 / Wednesday, September 30, 2009 / Notices
Notice of this meeting is given under
the Federal Advisory Committee Act
(Pub. L. 92–463, 5 U.S.C., App. 2).
Dated: September 24, 2009.
Judith Sparrow,
Office of Programs and Coordination, Office
of the National Coordinator for Health
Information Technology.
[FR Doc. E9–23460 Filed 9–29–09; 8:45 am]
BILLING CODE 4150–45–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Toxicology Program (NTP);
NTP Interagency Center for the
Evaluation of Alternative Toxicological
Methods (NICEATM); Availability of the
Interagency Coordinating Committee
on the Validation of Alternative
Methods (ICCVAM) Test Method
Evaluation Report: The Reduced
Murine Local Lymph Node Assay, an
Alternative Test Method Using Fewer
Animals To Assess the Allergic
Contact Dermatitis Potential of
Chemicals and Products; Availability
of ICCVAM Recommended Murine
Local Lymph Node Assay Performance
Standards; Notice of Transmittal to
Federal Agencies of ICCVAM Test
Method Recommendations for the
Reduced Murine Local Lymph Node
Assay, Updated Murine Local Lymph
Node Assay Test Method Protocol, and
Murine Local Lymph Node Assay Test
Method Performance Standards
CPrice-Sewell on DSKGBLS3C1PROD with NOTICES
AGENCY: National Institute of
Environmental Health Sciences
(NIEHS), National Institutes of Health
(NIH)
ACTION: Availability of ICCVAM Test
Method Evaluation Report (TMER) and
Recommended Test Method
Performance Standards; Notice of
Transmittal.
SUMMARY: NICEATM announces
availability of the ICCVAM Test Method
Evaluation Report: The Reduced Murine
Local Lymph Node Assay: An
Alternative Test Method Using Fewer
Animals to Assess the Allergic Contact
Dermatitis Potential of Chemicals and
Products (NIH Publication 09–6439).
The TMER provides ICCVAM’s
evaluation and recommendations for the
reduced Murine Local Lymph Node
Assay (rLLNA) test method as a
reduction alternative that uses fewer
animals compared to the traditional
Murine Local Lymph Node Assay
(LLNA) for assessing the potential of test
substances to cause allergic contact
dermatitis (ACD). The report includes
ICCVAM’s recommendations on (a) the
usefulness and limitations of the
VerDate Nov<24>2008
14:56 Sep 29, 2009
Jkt 217001
rLLNA, (b) an updated ICCVAM LLNA
test method protocol, which includes
the procedures for conducting the
rLLNA, (c) future studies to further
characterize the usefulness and
limitations of the rLLNA, and (d) rLLNA
test method performance standards. The
TMER includes the report of an
international independent scientific
peer review panel (hereafter, Panel) and
the final rLLNA background review
document (BRD). The BRD provides the
data and analyses used to evaluate the
current validation status of the rLLNA
test method for assessing the ACD
potential of chemicals and products.
ICCVAM concluded that the scientific
validity of the rLLNA has been
adequately evaluated and that the
performance of the rLLNA, when
conducted in accordance with the
ICCVAM-recommended LLNA test
method protocol, is sufficient to
distinguish between skin sensitizers and
non-sensitizers. ICCVAM also
concluded that the rLLNA would reduce
animal use by 40% for each test
compared to the traditional, multi-dose
LLNA. Accordingly, ICCVAM
recommends that the rLLNA test
method should be routinely considered
before conducting the traditional, multidose LLNA, and used where appropriate
as the initial test to determine the
potential of chemicals and products to
produce ACD. For testing situations that
require dose-response information,
rLLNA-positive substances will need to
be tested with the traditional multi-dose
LLNA. This testing should be done
using the updated ICCVAMrecommended test method protocol,
which reduces animal use by 20%
compared to the original ICCVAMrecommended test method protocol by
decreasing the minimum number of
animals per dose group from five to
four.
NICEATM also announces availability
of the ICCVAM Recommended
Performance Standards: Murine Local
Lymph Node Assay (NIH Publication
09–7357). The ICCVAM recommends
that LLNA test method performance
standards can be used to efficiently
evaluate the validity of modified
versions of the LLNA that are
mechanistically and functionally similar
to the traditional LLNA. The traditional
LLNA test method is the reference test
method used as the basis for
establishing the LLNA performance
standards. The performance standards
specify the essential test method
components that must be included in a
modified LLNA in order to use the
performance standards to evaluate the
validity of the modified test method.
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
The performance standards also specify
a minimum list of reference substances
to evaluate the accuracy and reliability
of the modified test method, and the
accuracy and reliability values that must
be achieved in order for the modified
test method to be considered equal to or
better than the traditional LLNA.
Electronic copies of the ICCVAM
rLLNA TMER and the report on
ICCVAM-recommended LLNA
performance standards are available
from the NICEATM–ICCVAM Web site
at https://iccvam.niehs.nih.gov or by
contacting NICEATM (see FOR FURTHER
INFORMATION CONTACT). The two reports
have been forwarded to U.S. Federal
agencies for regulatory and other
acceptance considerations, where
applicable. Responses will be posted on
the NICEATM–ICCVAM website as they
are received.
FOR FURTHER INFORMATION CONTACT: Dr.
William S. Stokes, Director, NICEATM,
NIEHS, P.O. Box 12233, Mail Stop: K2–
16, Research Triangle Park, NC 27709,
(telephone) 919–541–2384, (fax) 919–
541–0947, (e-mail)
niceatm@niehs.nih.gov. Courier address:
NICEATM, NIEHS, Room 2034, 530
Davis Drive, Morrisville, NC 27560.
SUPPLEMENTARY INFORMATION:
Background
The U.S. Consumer Product Safety
Commission (CPSC) nominated several
new versions and applications of the
LLNA to ICCVAM in 2007 for
evaluation of their scientific validity
(https://iccvam.niehs.nih.gov/methods/
immunotox/llnadocs/
CPSC_LLNA_nom.pdf). The nomination
requested that ICCVAM assess the
validation status of: (1) the LLNA limit
dose procedure (i.e., the rLLNA); (2)
three modified LLNA test method
protocols that do not require the use of
radioactive materials; (3) the use of the
LLNA to test mixtures, aqueous
solutions, and metals (applicability
domain for the LLNA); and (4) the use
of the LLNA to determine ACD potency
categories for hazard classification.
NICEATM published a Federal Register
notice (72 FR 27815) requesting public
comments on the appropriateness and
relative priority of the CPSC-nominated
LLNA activities, the development of test
method performance standards for the
LLNA, the nomination of scientists to
serve on the Panel, and the submission
of data from LLNA testing that related
to the CPSC-nominated LLNA activities,
as well as corresponding data from
human and other animal studies. After
considering public comments and
comments from the Scientific Advisory
Committee on Alternative Toxicological
E:\FR\FM\30SEN1.SGM
30SEN1
Agencies
[Federal Register Volume 74, Number 188 (Wednesday, September 30, 2009)]
[Notices]
[Pages 50211-50212]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-23460]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the National Coordinator for Health Information
Technology
HIT Policy Committee Advisory Meeting; Notice of Two-Day Meeting
AGENCY: Office of the National Coordinator for Health Information
Technology, HHS.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Office of the National Coordinator for Health
Information Technology (ONC). The meeting will be open to the public.
Name of Committee: HIT Policy Committee.
General Function of the Committee: To provide recommendations to
the National Coordinator on a policy framework for the development and
adoption of a nationwide health information technology infrastructure
that permits the electronic exchange and use of health information as
is consistent with the Federal Health IT Strategic Plan and that
includes recommendations on the areas in which standards,
implementation specifications, and certification criteria are needed.
Date and Time: The two-day meeting will be held on October 27 and
October 28, 2009, from 10 a.m. to 5:15 p.m./Eastern Time on October
27th, and 8:30 a.m. to 3 p.m./Eastern Time on October 28th.
Location: The Omni Shoreham Hotel, 2500 Calvert Street, NW.,
Washington, DC. The hotel telephone number is 202-234-0700.
Contact Person: Judy Sparrow, Office of the National Coordinator,
HHS, 330 C Street, SW., Washington, DC 20201, 202-205-4528, Fax: 202-
690-6079, e-mail: judy.sparrow@hhs.gov. Please call the contact person
for up-to-date information on this meeting. A notice in the Federal
Register about last minute modifications that impact a previously
announced advisory committee meeting cannot always be published quickly
enough to provide timely notice.
Agenda: The committee will hear presentations from the Meaningful
Use, Certification/Adoption, and Information Exchange Workgroups. In
addition, invited experts will provide testimony on the mapping of core
Meaningful Use objectives and existing measures to medical specialties,
small practices, and small hospitals. ONC intends to make background
material available to the public no later than two (2) business days
prior to the meeting. If ONC is unable to post the background material
on its Web site prior to the meeting, it will be made publicly
available at the location of the advisory committee meeting, and the
background material will be posed on ONC's Web site after the meeting,
at https://healthit.hhs.gov.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before
October 18, 2009. Oral comments from the pubic will be scheduled
approximately 5 p.m./Eastern Time on October 27th, and 12:30 p.m./
Eastern Time on October 28th. Time allotted for each public comment is
limited to two minutes. If the number of speakers requesting to comment
is greater than can be reasonably accommodated during the scheduled
open public hearing session, ONC will take written comments after the
meeting until close of business.
Persons attending ONC's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical
outlets.
ONC welcomes the attendance of the public at its advisory committee
meetings. Seating is limited at the location, and ONC will make every
effort to accommodate persons with physical disabilities or special
needs. If you require special accommodations due to a disability,
please contact Judy Sparrow at least seven (7) days in advance of the
meeting.
ONC is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at https://healthit.hhs.gov for
procedures on public conduct during advisory committee meetings.
[[Page 50212]]
Notice of this meeting is given under the Federal Advisory
Committee Act (Pub. L. 92-463, 5 U.S.C., App. 2).
Dated: September 24, 2009.
Judith Sparrow,
Office of Programs and Coordination, Office of the National Coordinator
for Health Information Technology.
[FR Doc. E9-23460 Filed 9-29-09; 8:45 am]
BILLING CODE 4150-45-P